Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-05

Study Completion Date

2022-03-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to determine the safety of three different doses of sc-rAAV2.5IL-1Ra delivered by intra-articular injection into one knee joint of patients with moderate OA of the knee.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra-articular Injection of MSCs in Treatment of Knee OA

NCT03028428

Osteoarthritis Stem Cells MSC

UNKNOWN PHASE2

A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis

NCT02838069

Osteoarthritis

COMPLETED PHASE2

Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis

NCT03602872

Knee Osteoarthritis

WITHDRAWN PHASE1

Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

NCT02003131

Osteoarthritis of the Knee

WITHDRAWN PHASE1/PHASE2

Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis

NCT04240873

Osteoarthritis, Knee

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Dose Group

Subjects will receive a single intra-articular 2mL injection consisting of 10{11} viral genomes.

Group Type EXPERIMENTAL

sc-rAAV2.5IL-1Ra

Intervention Type DRUG

Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Medium Dose Group

Subjects will receive a single intra-articular 2mL injection consisting of 10{12} viral genomes.

Group Type EXPERIMENTAL

sc-rAAV2.5IL-1Ra

Intervention Type DRUG

Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

High Dose Group

Subjects will receive a single intra-articular 2mL injection consisting of 10{13} viral genomes.

Group Type EXPERIMENTAL

sc-rAAV2.5IL-1Ra

Intervention Type DRUG

Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sc-rAAV2.5IL-1Ra

Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AAVIL-1Ra IL-1Ra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-80 years
* Gender: both males and females
* Target disease: Moderate OA of the knee
* Persistent symptoms, despite standard NSAID
* Absence of clinically significant abnormal values for the following:
* Complete blood count
* Prothrombin Time, Activated partial thromboplastin time
* Blood chemistry (Glucose, Na, K, Cl, CO2, BUN, creatinine, Ca, PO4, magnesium, uric acid)
* Liver function tests (amylase, total bilirubin, alkaline phosphate, GGT, AST, ALT, total protein, albumin)
* Able and willing to return to the Mayo Clinic for follow-up visits, as required by this study
* Able undergo MRI of the knee
* Subjects should be able to give appropriate consent.
* Potential subjects should have failed a three-month trial of a minimum of two conservative therapies before being considered for this trial. These conservative therapies include: activity modification, weight loss, physical therapy, and anti-inflammatory or injection therapy.

Exclusion Criteria

* Pregnant, or currently breast-feeding
* Ongoing infectious disease including HIV, HTLV, hepatitis, syphilis or tuberculosis positive
* Individuals who have OA as part of another syndrome (e.g. Ehler's Danlos, Stickler syndrome, etc.)
* Systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis.
* Clinically significant cardiovascular, renal, hepatic, endocrine disease, diabetes, cancer, autoimmune diseases; a serious infection or major operation within 30 days of enrollment; a history of untreated psychiatric disease or recent history of alcoholism or drug addiction.
* Currently taking immunosuppressant medications
* Anticipated major surgery during the study period.
* Individuals involved in another interventional protocol, or have been treated under one within the last 3 months.
* Intra-articular therapy in the index knee within the previous 3 months.
* Surgery to the target knee within 6 months prior to screening.
* Surgery to other weight bearing joints if it will interfere with knee assessments
* Prior articular transplant procedures
* Orthopedic hardware or implantable devices in the index knee
* Prior reconstruction surgery to the target knee within 12 months
* X-ray findings of acute fractures
* Known severe loss of bone density, and/or severe bone or joint deformity in the target knee.
* Significant target knee infection or overlying skin disorder/infection within the previous 6 months prior to study enrollment
* Require cane or other assistive device for walking
* Symptomatic OA of the hips, spine or ankle if it would interfere with the evaluation of the target knee,
* History of documented nerve damage in the affected limb, or vascular insufficiency,
* Condition requiring use of systemic steroids,
* Coagulation disorder.
* Patients with unstable knees
* Temperature above 99.5o F.
* Identification as a member of a vulnerable population.
* BMI greater than 40.
* History of allergy to local anesthetics
* Currently taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within the 3 months prior to entry in the study.
* Any illness or condition which, in the investigators' judgement will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No